GPCR NASDAQ
Structure Therapeutics Inc.
1W: -5.8%
1M: -38.5%
3M: -54.5%
YTD: -68.4%
1Y: -18.3%
3Y: -68.1%
$21.55
+0.45 (+2.13%)
Weekly Expected Move ±7.5%
$18
$20
$21
$23
$24
Credit Risk of going bust: lower than 80% of companies Debt: 0.5% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.01 (down 99.9%), Structure Therapeutics Inc. would be worth roughly what it owes.
Total debt $6.2M against a stock market value of $1.24B.
Distance to default 9.66 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $3.1M (short-term plus half of long-term), stock volatility 60.7%; Altman Z'' 23.53. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.01 (down 99.9%), Structure Therapeutics Inc. would be worth roughly what it owes.
Total debt $6.2M against a stock market value of $1.24B.
Distance to default 9.66 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $3.1M (short-term plus half of long-term), stock volatility 60.7%; Altman Z'' 23.53. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
1 neutral
0 bearish
Articles (24h)
1
Hourly Sentiment (24h)
0.30
Neutral
1 bullish
2 neutral
0 bearish
Articles (7d)
3
Daily Sentiment (7 Days)
Articles (100)
Buy, Sell or Hold LLY Stock? Key Factors to Watch Ahead of Q3 Earnings
How Will Novo's GLP-1 Portfolio Sales Aid Upcoming Q3 Results?
Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Stock Has Consensus Price Target of $110.91 According to Brokerages
How Will Eli Lilly's GLP-1 Portfolio Sales Aid Upcoming Q3 Results?
Structure Therapeutics (NASDAQ:GPCR) Sets New 52-Week Low – Here’s Why
Novo Down 11% in a Month: How Should Investors Approach the Stock Now?
LLY Stock Down 2% in 3 Months: Is the Dip a Buying Opportunity?
These ten healthcare stocks posted the biggest one-month losses
Can Novo's Licensing Strategy Build Its Next Wave of Oral Medicines?
Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Stock Rated “Moderate Buy” by Sell-Side Brokerages
Beyond GLP-1 injectables, who wins the next phase for obesity drugs?
Can Novo's Rare Disease Pipeline Add a New Growth Pillar Beyond GLP-1?
10 mid-cap U.S. healthcare stocks with the weakest momentum grades
LLY Stock Down Around 7% in a Month: Buy the Dip or Stay Cautious?
Novo Falls 5% in a Week: How Should Investors Approach the Stock Now?
Will Morgan Stanley's NVO Downgrade Deepen Patent and Rival Woes?
Structure Therapeutics falls after trial data for lead obesity drugs
Novo Nordisk's Semaglutide Meets Goal in Pediatric Obesity Study
Structure Therapeutics Reports Positive Clinical Data Across Oral Small Molecule Amylin and GLP-1 Programs for Chronic Weight Management
Can CagriSema Help Novo Nordisk Close the Gap With LLY in Obesity?
NVO vs. GPCR: Which Obesity Stock Is the Better Buy Right Now?
Can Awiqli Help Novo Nordisk Build a New Growth Engine Beyond GLP-1s?
How Does LLY's Q2 GLP-1 Portfolio Performance Stack Up Against NVO's?
LLY Up Around 6% Post Robust Q2 Results: Buy, Sell or Hold the Stock?
Can Novo Nordisk's GLP-1 Pill Momentum Offset LLY's Growing Edge?
LLY's Foundayo Posts $98M in Q2 Sales: What's Next for the Oral GLP-1?
Novo Nordisk Dips 4% in a Month: How Should Investors Play the Stock?
SA Asks: What's the outlook for Big Pharma M&A?
Novo Nordisk Before Q2 Earnings: How Should Investors Play the Stock?
How Will Ozempic and Wegovy Sales Aid NVO's Upcoming Q2 Results?
LLY's Retatrutide Nears 2027 Filing With Two More Phase III Wins
How Will Eli Lilly's GLP-1 Portfolio Sales Aid Upcoming Q2 Results?
NVO Challenges LLY Ads in GLP-1 Battle: Why the Lawsuit Matters Now
Does EU Approval of Wegovy Pill Change NVO's Competitive Story?
NVO Rallies 11% in a Month: How Should Investors Play the Stock?
LLY Hits Another Record High: Is the Stock Too Expensive to Buy Now?
Can Medicare Bridge Help Novo Nordisk Defend Its GLP-1 Leadership?
Lilly Up Around 7% in a Week: Should You Buy, Sell or Hold the Stock?
Can Eli Lilly's New Drugs Fuel Growth Beyond Its GLP-1 Blockbusters?
Can Wegovy Pill's Europe Push Help NVO Offset Mounting Pressures?
Novo Nordisk Gains 7% in a Week: How Should Investors Play the Stock?
Can Eli Lilly's Clinical Momentum Keep the Stock at Record Highs?
12 Health Care Stocks Moving In Monday's After-Market Session
Can Wegovy Pill's Rapid Uptake Give Novo Nordisk an Edge Over LLY?
Can Eli Lilly's 2026 Acquisition Spree Diversify Growth Beyond GLP-1s?
LLY Rises 14% in a Month: Should You Hold as Obesity Growth Continues?
LLY Stock Gains 4% to All-Time High: Is Obesity Access the Catalyst?
Can EU Label Expansions of NVO's GLP-1 Drugs Spur Sales Growth?
SA Asks: What are the most attractive biotech stocks right now?
This Biotech Is Up 60%. A Top Healthcare Fund Just Bought Another $11 Million
LLY Reports Third Phase III Win for Next-Generation Obesity Drug
Can Mounjaro, Zepbound & Foundayo Keep Fueling LLY's Growth Story?
Monashee Scales Back Its Bet on Structure Therapeutics
This Obesity Drug Stock Has Jumped 60% as Phase 3 Plans Advance. A Fund Just Sold $4.7 Million
Can Novo Nordisk Sustain Its GLP-1 Edge Amid Lilly's Growing Pressure?
Lilly Bets on Next-Generation Obesity Drugs to Stay Ahead
NVO Rallies 21% in a Month: How Should Investors Play the Stock?
Structure Therapeutics Stock Is Up 47%, but One Fund Just Fully Exited a $2.6 Million Position
Structure Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
LLY Stock Pops 16% After Beat-and-Raise Q1: Buy, Hold or Take Profits?
Lilly's Oral GLP-1 Pill Foundayo Starts Strong in Oral Obesity Market
Novo Nordisk Before Q1 Earnings: How Should Investors Play the Stock?
Structure Therapeutics to Present Aleniglipron, Amylin and Combination Data at the American Diabetes Association 86th Scientific Sessions
LLY's Oral GLP-1 Pill Foundayo Shows Heart Benefits in Diabetes Study
3 Ways to Invest in the Growing GLP-1 Weight Loss Market
LLY Stock Down as FDA Asks for More Safety Data on Oral Obesity Pill
How Will Mounjaro and Zepbound Sales Aid LLY's Upcoming Q1 Results?
Does NVO Face Rising Competitive Pressure on LLY's Foundayo Approval?
Aberdeen Group plc Sells 322,000 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR
How to Play Lilly Stock Post Oral Obesity Pill Foundayo's Approval
Capricorn Fund Managers Ltd Invests $17.57 Million in Structure Therapeutics Inc. Sponsored ADR $GPCR
Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Given Consensus Rating of “Moderate Buy” by Brokerages
LLY Stock Up on GLP-1 Pill Approval: Can it Outpace NVO's Wegovy Pill?
Exchange Traded Concepts LLC Sells 32,241 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR
What's Going On With Structure Therapeutics Stock On Wednesday?
NVO vs. GPCR: Which Obesity Stock is the Better Buy Right Now?
Structure Therapeutics Slides 28% This Year as $6 Million Stake Emerges
HC Wainwright Has Positive Forecast for GPCR FY2027 Earnings
Why Did Eli Lilly Stock Slide 6% Despite Strong GLP-1 Momentum?
Structure Therapeutics rises on mid-stage data for oral GLP-1
Structure Therapeutics Stock Explodes As Much-Awaited Experimental Oral Drug Trial Shows Weight Loss Of 16%
Structure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron
ArrowMark Colorado Holdings LLC Boosts Stock Position in Structure Therapeutics Inc. Sponsored ADR $GPCR
3 Companies at the Forefront of the GLP-1 Pill Wars
Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Given Consensus Rating of “Moderate Buy” by Brokerages
Research Analysts Offer Predictions for GPCR Q1 Earnings
Lilly Stock Down 5% in a Month: Should You Buy Now or Steer Clear?
Structure Therapeutics Stock Surges 200% This Past Year as One Fund Cuts Stake by $15.5 Million
Structure Therapeutics reports Q4 results
Structure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights
Here are the quant ratings of OZEM’s top holdings amid Novo's selloff
Novo Nordisk stock tumbles as next-gen obesity shot underperforms Lilly’s tirzepatide
Nxera Pharma Licenses GPCR-targeted Program to Newly Founded Spin-out Company
Principal Financial Group Inc. Decreases Stock Holdings in Structure Therapeutics Inc. Sponsored ADR $GPCR
Mission Wealth Management LP Acquires New Stake in Structure Therapeutics Inc. Sponsored ADR $GPCR
This Healthcare Company Believes Its GLP-1 Pill Could Be "Next in Line" After Novo Nordisk and Eli Lilly. Its Valuation Is a Fraction of Theirs.
Healthy Returns: Structure Therapeutics CEO on its obesity pill, combinations and future of GLP-1s
Structure CEO Ray Stevens talks its obesity drug portfolio
A 10% Owner Of Structure Therapeutics Shed Shares
Can This Stock Double Again in 2026?